Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Insights, Forecast to 2028
SKU ID : QYR-20487677 | Publishing Date : 14-Mar-2022 | No. of pages : 114
Detailed TOC of Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Insights, Forecast to 2028
1 Report Business Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Therapeutics
1.2.3 Diagnostics
1.3 Market by Application
1.3.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals and Clinics
1.3.3 Cancer Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Perspective (2017-2028)
2.2 NTRK Fusion Gene Positive Advanced Solid Tumor Growth Trends by Region
2.2.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Region (2017-2022)
2.2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Region (2023-2028)
2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Dynamics
2.3.1 NTRK Fusion Gene Positive Advanced Solid Tumor Industry Trends
2.3.2 NTRK Fusion Gene Positive Advanced Solid Tumor Market Drivers
2.3.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Challenges
2.3.4 NTRK Fusion Gene Positive Advanced Solid Tumor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Revenue
3.1.1 Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Revenue (2017-2022)
3.1.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Players (2017-2022)
3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue
3.4 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Concentration Ratio
3.4.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue in 2021
3.5 NTRK Fusion Gene Positive Advanced Solid Tumor Key Players Head office and Area Served
3.6 Key Players NTRK Fusion Gene Positive Advanced Solid Tumor Product Solution and Service
3.7 Date of Enter into NTRK Fusion Gene Positive Advanced Solid Tumor Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NTRK Fusion Gene Positive Advanced Solid Tumor Breakdown Data by Type
4.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Type (2017-2022)
4.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Type (2023-2028)
5 NTRK Fusion Gene Positive Advanced Solid Tumor Breakdown Data by Application
5.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Application (2017-2022)
5.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2017-2028)
6.2 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type
6.2.1 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
6.2.2 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028)
6.2.3 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Type (2017-2028)
6.3 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application
6.3.1 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
6.3.2 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028)
6.3.3 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Application (2017-2028)
6.4 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country
6.4.1 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022)
6.4.2 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2017-2028)
7.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type
7.2.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
7.2.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028)
7.2.3 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Type (2017-2028)
7.3 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application
7.3.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
7.3.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028)
7.3.3 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Application (2017-2028)
7.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country
7.4.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022)
7.4.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2017-2028)
8.2 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type
8.2.1 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
8.2.2 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028)
8.2.3 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Type (2017-2028)
8.3 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application
8.3.1 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
8.3.2 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028)
8.3.3 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Application (2017-2028)
8.4 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region
8.4.1 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2017-2022)
8.4.2 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2017-2028)
9.2 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type
9.2.1 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
9.2.2 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028)
9.2.3 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Type (2017-2028)
9.3 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application
9.3.1 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
9.3.2 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028)
9.3.3 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Application (2017-2028)
9.4 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country
9.4.1 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022)
9.4.2 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2017-2028)
10.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type
10.2.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
10.2.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028)
10.2.3 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Type (2017-2028)
10.3 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application
10.3.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
10.3.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028)
10.3.3 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Application (2017-2028)
10.4 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country
10.4.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022)
10.4.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.1.4 Bayer Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.1.5 Bayer Recent Developments
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Details
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.2.4 Teva Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.2.5 Teva Pharmaceuticals Recent Developments
11.3 Empire Genomics
11.3.1 Empire Genomics Company Details
11.3.2 Empire Genomics Business Overview
11.3.3 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.3.4 Empire Genomics Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.3.5 Empire Genomics Recent Developments
11.4 SeraCare Life Sciences
11.4.1 SeraCare Life Sciences Company Details
11.4.2 SeraCare Life Sciences Business Overview
11.4.3 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.4.4 SeraCare Life Sciences Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.4.5 SeraCare Life Sciences Recent Developments
11.5 F. Hoffmann-La Roche
11.5.1 F. Hoffmann-La Roche Company Details
11.5.2 F. Hoffmann-La Roche Business Overview
11.5.3 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.5.4 F. Hoffmann-La Roche Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.5.5 F. Hoffmann-La Roche Recent Developments
11.6 NeoGenomics Laboratories
11.6.1 NeoGenomics Laboratories Company Details
11.6.2 NeoGenomics Laboratories Business Overview
11.6.3 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.6.4 NeoGenomics Laboratories Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.6.5 NeoGenomics Laboratories Recent Developments
11.7 Glaxosmithkline
11.7.1 Glaxosmithkline Company Details
11.7.2 Glaxosmithkline Business Overview
11.7.3 Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.7.4 Glaxosmithkline Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.7.5 Glaxosmithkline Recent Developments
11.8 OncoDNA
11.8.1 OncoDNA Company Details
11.8.2 OncoDNA Business Overview
11.8.3 OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.8.4 OncoDNA Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.8.5 OncoDNA Recent Developments
11.9 Merck & Co.
11.9.1 Merck & Co. Company Details
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.9.4 Merck & Co. Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.9.5 Merck & Co. Recent Developments
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Company Details
11.10.2 Daiichi Sankyo Business Overview
11.10.3 Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.10.4 Daiichi Sankyo Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.10.5 Daiichi Sankyo Recent Developments
11.11 S Deciphera Pharmaceuticals
11.11.1 S Deciphera Pharmaceuticals Company Details
11.11.2 S Deciphera Pharmaceuticals Business Overview
11.11.3 S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Introduction
11.11.4 S Deciphera Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
11.11.5 S Deciphera Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Figures, Tables and Charts Available in Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Insights, Forecast to 2028
List of TablesTable 1. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Therapeutics
Table 3. Key Players of Diagnostics
Table 4. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region (2017-2022)
Table 8. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region (2023-2028)
Table 10. NTRK Fusion Gene Positive Advanced Solid Tumor Market Trends
Table 11. NTRK Fusion Gene Positive Advanced Solid Tumor Market Drivers
Table 12. NTRK Fusion Gene Positive Advanced Solid Tumor Market Challenges
Table 13. NTRK Fusion Gene Positive Advanced Solid Tumor Market Restraints
Table 14. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Share by Players (2017-2022)
Table 16. Global Top NTRK Fusion Gene Positive Advanced Solid Tumor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor as of 2021)
Table 17. Ranking of Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players NTRK Fusion Gene Positive Advanced Solid Tumor Product Solution and Service
Table 21. Date of Enter into NTRK Fusion Gene Positive Advanced Solid Tumor Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Type (2017-2022)
Table 25. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Type (2023-2028)
Table 27. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Share by Application (2017-2022)
Table 29. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Share by Application (2023-2028)
Table 31. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2023-2028) & (US$ Million)
Table 61. Bayer Company Details
Table 62. Bayer Business Overview
Table 63. Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 64. Bayer Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 65. Bayer Recent Developments
Table 66. Teva Pharmaceuticals Company Details
Table 67. Teva Pharmaceuticals Business Overview
Table 68. Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 69. Teva Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 70. Teva Pharmaceuticals Recent Developments
Table 71. Empire Genomics Company Details
Table 72. Empire Genomics Business Overview
Table 73. Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 74. Empire Genomics Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 75. Empire Genomics Recent Developments
Table 76. SeraCare Life Sciences Company Details
Table 77. SeraCare Life Sciences Business Overview
Table 78. SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 79. SeraCare Life Sciences Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 80. SeraCare Life Sciences Recent Developments
Table 81. F. Hoffmann-La Roche Company Details
Table 82. F. Hoffmann-La Roche Business Overview
Table 83. F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 84. F. Hoffmann-La Roche Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 85. F. Hoffmann-La Roche Recent Developments
Table 86. NeoGenomics Laboratories Company Details
Table 87. NeoGenomics Laboratories Business Overview
Table 88. NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 89. NeoGenomics Laboratories Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 90. NeoGenomics Laboratories Recent Developments
Table 91. Glaxosmithkline Company Details
Table 92. Glaxosmithkline Business Overview
Table 93. Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 94. Glaxosmithkline Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 95. Glaxosmithkline Recent Developments
Table 96. OncoDNA Company Details
Table 97. OncoDNA Business Overview
Table 98. OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 99. OncoDNA Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 100. OncoDNA Recent Developments
Table 101. Merck & Co. Company Details
Table 102. Merck & Co. Business Overview
Table 103. Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 104. Merck & Co. Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 105. Merck & Co. Recent Developments
Table 106. Daiichi Sankyo Company Details
Table 107. Daiichi Sankyo Business Overview
Table 108. Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 109. Daiichi Sankyo Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 110. Daiichi Sankyo Recent Developments
Table 111. S Deciphera Pharmaceuticals Company Details
Table 112. S Deciphera Pharmaceuticals Business Overview
Table 113. S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product
Table 114. S Deciphera Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022) & (US$ Million)
Table 115. S Deciphera Pharmaceuticals Recent Developments
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Type: 2021 VS 2028
Figure 2. Therapeutics Features
Figure 3. Diagnostics Features
Figure 4. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Application: 2021 VS 2028
Figure 5. Hospitals and Clinics Case Studies
Figure 6. Cancer Centers Case Studies
Figure 7. Others Case Studies
Figure 8. NTRK Fusion Gene Positive Advanced Solid Tumor Report Years Considered
Figure 9. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region: 2021 VS 2028
Figure 12. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Players in 2021
Figure 13. Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue in 2021
Figure 15. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY (2017-2028) & (US$ Million)
Figure 16. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2028)
Figure 17. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2028)
Figure 18. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Share by Country (2017-2028)
Figure 19. United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY (2017-2028) & (US$ Million)
Figure 22. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2028)
Figure 23. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2028)
Figure 24. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Share by Country (2017-2028)
Figure 25. Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY (2017-2028) & (US$ Million)
Figure 32. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2028)
Figure 33. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2028)
Figure 34. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Share by Region (2017-2028)
Figure 35. China NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 41. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY (2017-2028) & (US$ Million)
Figure 42. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2028)
Figure 43. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2028)
Figure 44. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Share by Country (2017-2028)
Figure 45. Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2028)
Figure 49. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2028)
Figure 50. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Share by Country (2017-2028)
Figure 51. Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. UAE NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Bayer Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 55. Teva Pharmaceuticals Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 56. Empire Genomics Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 57. SeraCare Life Sciences Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 58. F. Hoffmann-La Roche Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 59. NeoGenomics Laboratories Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 60. Glaxosmithkline Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 61. OncoDNA Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 62. Merck & Co. Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 63. Daiichi Sankyo Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 64. S Deciphera Pharmaceuticals Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2017-2022)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Keyplayers in Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Insights, Forecast to 2028
BayerTeva Pharmaceuticals
Empire Genomics
SeraCare Life Sciences
F. Hoffmann-La Roche
NeoGenomics Laboratories
Glaxosmithkline
OncoDNA
Merck & Co.
Daiichi Sankyo
S Deciphera Pharmaceuticals